Lawrence Fong

34.1k total citations · 9 hit papers
268 papers, 16.2k citations indexed

About

Lawrence Fong is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lawrence Fong has authored 268 papers receiving a total of 16.2k indexed citations (citations by other indexed papers that have themselves been cited), including 197 papers in Oncology, 123 papers in Immunology and 91 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lawrence Fong's work include Cancer Immunotherapy and Biomarkers (155 papers), Immunotherapy and Immune Responses (89 papers) and Prostate Cancer Treatment and Research (65 papers). Lawrence Fong is often cited by papers focused on Cancer Immunotherapy and Biomarkers (155 papers), Immunotherapy and Immune Responses (89 papers) and Prostate Cancer Treatment and Research (65 papers). Lawrence Fong collaborates with scholars based in United States, Spain and France. Lawrence Fong's co-authors include Edgar G. Engleman, Eric J. Small, Dirk G. Brockstedt, David Y. Oh, Yafei Hou, Serena S. Kwek, Toni K. Choueiri, Daniel P. Petrylak, Joaquim Bellmunt and Andrea Necchi and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Lawrence Fong

257 papers receiving 16.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

2017 2.4k citations Lawrence Fong, Toni K. Choueiri et al. profile →
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

2019 1.1k citations Cassandra D. Belair, Lawrence Fong et al. profile →
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

1999 919 citations Lawrence Fong et al. profile →
Systemic Immunity Is Required for Effective Cancer Immunotherapy

2017 687 citations Serena S. Kwek, Lawrence Fong et al. profile →
Dendritic Cells in Cancer Immunotherapy

2000 563 citations Lawrence Fong et al. profile →
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer

2020 464 citations David Y. Oh, Serena S. Kwek et al. profile →
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

2007 323 citations Eric J. Small, Brian I. Rini et al. Clinical Cancer Research profile →
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

2019 306 citations Lawrence Fong, Toni K. Choueiri et al. profile →
Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox

2021 273 citations David Y. Oh, Lawrence Fong profile →

Peers

Countries citing papers authored by Lawrence Fong

Since Specialization

Citations

This map shows the geographic impact of Lawrence Fong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence Fong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence Fong more than expected).

Fields of papers citing papers by Lawrence Fong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence Fong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence Fong. The network helps show where Lawrence Fong may publish in the future.

Co-authorship network of co-authors of Lawrence Fong

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence Fong. A scholar is included among the top collaborators of Lawrence Fong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence Fong. Lawrence Fong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identification and regulation of circulating tumor-TCR-matched cytotoxic CD4+ lymphocytes by KLRG1 in bladder cancer 2025 ·JCI Insight ·Serena S. Kwek, Hai Yang, Tony Li, Arielle Ilano, Eric D. Chow, Li Zhang, (unknown), (unknown), Averey Lea, Matthew Clark, (unknown), Yimin Shi, Elizabeth A. McCarthy, Sima P. Porten, Maxwell V. Meng, Chun Ye, Lawrence Fong, David Oh	0
2	45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma 2024 ·The Oncologist ·Toni K. Choueiri, Thomas Powles, David A. Braun, Lawrence Fong, Daniel J. George, Naomi B. Haas, David F. McDermott, Brian Shuch, Howard Gurney, Robert Meehan, (unknown), Sterling Wu, Aymen Elfiky, Robert J. Motzer	3
3	CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy 2024 ·Blood Advances ·Guy Ledergor, (unknown), Kaichun Wu, Elizabeth McCarthy, Axel Hyrenius‐Wittsten, (unknown), (unknown), (unknown), Serena S. Kwek, Alexander Cheung, Sophia Bylsma, Erik Hansen, Jeffrey L. Wolf, Sandy W. Wong, Nina Shah, Kole T. Roybal, Thomas Martin, Chun Ye, Lawrence Fong	19
4	PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways 2024 ·Cancer Immunology Research ·Jiuling Yang, (unknown), James R. Byrnes, Lisa L. Kirkemo, (unknown), Cassandra D. Belair, Oscar A. Aguilar, Lewis L. Lanier, James A. Wells, Lawrence Fong, Robert Blelloch	7
5	A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer. 2024 ·Journal of Clinical Oncology ·Evan Y. Yu, Luke T. Nordquist, Salim Yazji, Yisrael Katz, (unknown), (unknown), Mohamad A. Salkeni, Hamid Emamekhoo, Elisabeth I. Heath, Ivan de Kouchkovsky, Joshua M. Lang, Peter S. Nelson, James B. Breitmeyer, Lawrence Fong, Johann S. de Bono	0
6	Xaluritamig: a first step towards a new target, new mechanism for metastatic prostate cancer 2024 ·(unknown), Michael T. Schweizer, Jessica E. Hawley, Lawrence Fong, Evan Y. Yu	2
7	862 TLR9 agonism promotes cytotoxic T cell persistence and myeloid remodeling when combined with radiation therapy and PD-1 blockade in oligometastatic prostate cancer patients 2023 ·SHILAP Revista de lepidopterología ·(unknown), David Y. Oh, Anthony Wong, Katsuto Shinohara, Hao G. Nguyen, (unknown), (unknown), (unknown), Tony Li, (unknown), (unknown), Eliezer M. Van Allen, Li Zhang, Rahul Aggarwal, Terence W. Friedlander, Eric J. Small, Felix Y. Feng, Lawrence Fong	1
8	CD4+ T cells help myeloid-mediated killing of immune-evasive tumors 2023 ·Trends in cancer ·Kaichun Wu, Lawrence Fong	2
9	Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T 2020 ·Cancer Immunology Research ·Li Zhang, (unknown), Hai Yang, Jason Cham, Tao He, David Y. Oh, Nadeem A. Sheikh, Lawrence Fong	17
10	Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer 2016 ·Cancer Immunology Research ·Xiao X. Wei, (unknown), Serena S. Kwek, Jera Lewis, Vinh Dao, Li Zhang, Matthew R. Cooperberg, Charles J. Ryan, Amy Lin, Terence W. Friedlander, Brian Rini, Christopher Kane, Jeffry Simko, Peter R. Carroll, Eric J. Small, Lawrence Fong	30
11	Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects 2016 ·Cancer Research ·Nadeem A. Sheikh, Jason Cham, Li Zhang, Todd DeVries, Simon Letarte, (unknown), David Hamm, James Trager, Lawrence Fong	50
12	Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire 2016 ·Cancer Research ·David Y. Oh, Jason Cham, Li Zhang, (unknown), Serena S. Kwek, Mark Klinger, Malek Faham, Lawrence Fong	173
13	A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer 2015 ·Clinical Cancer Research ·Eric J. Small, Raymond S. Lance, Thomas A. Gardner, Lawrence I. Karsh, Lawrence Fong, Candice McCoy, Todd DeVries, Nadeem A. Sheikh, Debraj GuhaThakurta, Nancy N. Chang, Charles H. Redfern, Neal D. Shore	61
14	Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab 2015 ·Cancer Immunology Research ·Serena S. Kwek, Jera Lewis, Li Zhang, Vivian Weinberg, (unknown), Andrea Harzstark, Amy Lin, Charles J. Ryan, Eric J. Small, Lawrence Fong	50
15	Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients 2014 ·Proceedings of the National Academy of Sciences ·Courtney A. Crane, Kathryn Austgen, Kristen Haberthur, (unknown), Kara White Moyes, Lia Avanesyan, Lawrence Fong, Michael J. Campbell, Stewart Cooper, Scott A. Oakes, Andrew T. Parsa, Lewis L. Lanier	144
16	Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens 2014 ·Clinical Cancer Research ·Won Kim, Li Zhang, John H. Wilton, Gerald J. Fetterly, James L. Mohler, Vivian Weinberg, (unknown), Russell Z. Szmulewitz, Terence W. Friedlander, Lawrence Fong, Amy Lin, Andrea Harzstark, Arturo Molina, Eric J. Small, Charles J. Ryan	31
17	Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance 2014 ·The Journal of Experimental Medicine ·Imran S. Khan, Maria L. Mouchess, Menglei Zhu, Bridget Conley, Kayla J. Fasano, Yafei Hou, Lawrence Fong, Maureen A. Su, Mark S. Anderson	98
18	Shuffling the deck with CTLA-4 therapy: Deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patients 2014 ·OncoImmunology ·Edward Cha, Lawrence Fong	3
19	Microfluidic-Based Multiplex qRT-PCR Identifies Diagnostic and Prognostic microRNA Signatures in the Sera of Prostate Cancer Patients 2010 ·Cancer Research ·Felix Moltzahn, Adam B. Olshen, Lauren Baehner, Andrew S. Peek, Lawrence Fong, Hubert Stöppler, Jeffry Simko, Joan F. Hilton, Peter R. Carroll, Robert Blelloch	274
20	CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion 2008 ·Blood ·Brian D. Kavanagh, Shaun O’Brien, David Lee, Yafei Hou, Vivian Weinberg, Brian I. Rini, James P. Allison, Eric J. Small, Lawrence Fong	201

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact